As we get older, old, malfunctioning cells accumulate in our bodies. These so-called senescent cells contribute to chronic inflammation and can damage tissue. Researchers are trying to clear these cells in order to combat signs of ageing and promote healthy ageing.
One of the treatments being investigated in clinical practice uses a combination of two agents, dasatinib and quercetin. Smaller clinical trials show indications that this combination reduces senescent cells, but the results are not yet definitive. The dosages are low and the research is still in an early phase.
At the same time, scientists are increasingly focusing on better understanding the different types of senescent cells and their functions. It turns out that simply removing these cells can sometimes have disadvantages. For example, they can be part of vulnerable areas in blood vessels, where clearing them away can actually cause problems.
The future of this field of research lies in developing more precise therapies that do not tackle all senescent cells at once, but work in a targeted manner. That can help to better maintain the balance between benefits and drawbacks. Although the first treatments already exist, much is still needed to make this safe and effective.
These developments are important, because tackling these old cells can contribute to healthier ageing and the prevention of age-related complaints.
Source: Reason
